Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia…

GuidelineNeurologia· May 2026

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

R Sánchez-Valle, D Alcolea, G Amer Ferrer … Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment

Read paper

Cognitive & DementiaGuidelineClinical practiceQ2IF 2.4

The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of alzheimer disease, but is not free of challenges.

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

R Sánchez-Valle … Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment

Neurologia · May 2026 · Q2 in Neurology

Background

Two anti-amyloid monoclonal antibodies (mAb) have recently been approved by the European Commission for the treatment of Alzheimer disease (alzheimer disease).

Methods

Noted concerns about equity of access and implementation into current care, particularly if insufficient resources are allocated to this implementation.

More results

DEVELOPMENT: Fifty-seven members of the study group participated in the consensus process (January-September 2025), which includes recommendations on criteria for selecting candidates, adverse reactions, monitoring, criteria for suspension of treatment, shared physician-patient decision-making, and requirements of prescribing centres.

More results

This document will require updates in line with new knowledge and/or approval of new drugs in this class.

“

Conclusion · 1 of 3

The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of alzheimer disease, but is not free of challenges.

Conclusion · 2 of 3

The participating experts showed a high level of consensus on basic clinical and practical considerations, with the requirements of prescribing centres and criteria for treatment suspension being the areas that generated the most debate.

Conclusion · 3 of 3

Participants noted concerns about equity of access and implementation into current care, particularly if insufficient resources are allocated to this implementation.

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

Related papers